Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04090853
Other study ID # BL1119
Secondary ID
Status Withdrawn
Phase N/A
First received
Last updated
Start date October 1, 2019
Est. completion date July 8, 2020

Study information

Verified date May 2023
Source Venus Concept
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Open-label, baseline-controlled, multi-center study evaluating a 1064 nm diode laser, pulsed electromagnetic fields and vacuum assisted radio frequency for non-invasive fat reduction of the abdomen and flanks.


Description:

The study will enroll up to 200 subjects requesting non-invasive lipolysis of the abdomen and flanks. Each subject will receive up to 3 study treatments of the diode laser and up to 3 treatments of the pulsed electromagnetic fields and vacuum assisted radio frequency study treatments. Subjects will be followed at 24 weeks post diode treatments to observe their satisfaction with treatment outcomes.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date July 8, 2020
Est. primary completion date July 8, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Able to read, understand and voluntarily provide written informed consent. 2. Healthy male or female, = 18 years of age seeking treatment for unwanted fat in the flanks and or abdomen 3. BMI score is less than 35. 4. Able and willing to comply with the treatment/follow-up schedule and requirements. 5. Women of child-bearing age are required to be using a reliable method of birth control at least 3 months prior to study enrollment and for the duration of the study, and have a negative Urine Pregnancy test at baseline. Exclusion Criteria: 1. Pregnant, intending to become pregnant, postpartum or nursing in the last 6 months. 2. Any previous liposuction/lipo-sculpture or any type of surgical procedure in the treatment area in the past 12 months. 3. History of immunosuppression/immune deficiency disorders (including AIDS and HIV infection) or use of immunosuppressive medications, 6 months prior to and during the course of the study. 4. History of hyperlipidemia, diabetes mellitus, hepatitis, blood coagulopathy or excessive bleeding. 5. Use of antiplatelet medications (81 mg acetylsalicylic acid daily permitted), anticoagulants, thrombolytics or anti-inflammatory medications within 2 weeks of treatment. 6. Having a history of skin cancer or any other cancer in the areas to be treated, including presence of malignant or pre-malignant pigmented lesions. 7. Having a permanent implant in the treatment area such as metal plates or an injected chemical substance such as silicone or parenteral gold therapy (gold sodium thiomalate). 8. Use of medications, herbs, food supplements, and vitamins known to induce photosensitivity to light exposure at the wavelength used or history of photosensitivity disorder. 9. Suffering from significant skin conditions in the treatment area or inflammatory skin conditions including but not limited to open lacerations, abrasions, herpes sores, cold sores, active infections. 10. Tattoos in the treatment area. 11. Poor skin quality (severe laxity). 12. Abdominal wall, muscular abnormality or hernia on physical examination. 13. Use of retinoids such as oral isotretinoin (Accutane™) within the past six months or during course of the study. 14. History of keloid or hypertrophic scar formation or poor wound healing in the treatment area. 15. As per the investigator's discretion, any physical or mental condition which may make it unsafe for the subject to participate. 16. Unable or unlikely to refrain from sun exposure, artificial tanning, including the use of tanning booths, prior to (six weeks) and during the course of the evaluation.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Venus Bliss
The investigational device (Venus Bliss™) is a non-invasive medical aesthetic device designed for body contouring. The device is comprised of a console, four 1064 nm diode laser applicators (60 mm x 60 mm). A belt is included to allow the operator to secure the laser applicators on the lipolysis treatment area, allowing hands free operation. The device uses vacuum assisted radiofrequency (RF) and PEMF (pulsed electromagnetic field) technology which has been shown in clinical studies to be safe and effective in body circumferential reduction and skin tightening.

Locations

Country Name City State
United States Shah Aesthetic Surgery Denver Colorado
United States Medical Management Solutions INC Foxboro Massachusetts
United States SRS Dermatology Woodmere New York

Sponsors (1)

Lead Sponsor Collaborator
Venus Concept

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Patient Overall Satisfaction Patients rate their satisfaction with treatment outcomes at the final follow up visit using a patient survey by answering 12 questions Week 26
Primary Patient Treatment Satisfaction Patients rate their treatment satisfaction using a 5 point Likert Scale. The Likert scale ranges from 1 = very unsatisfied 2 = unsatisfied 3 = neutral 4 = satisfied 5 = very satisfied Week 26
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05760248 - Safety and Efficacy Study of 10XB-101 in Adults With Bilateral Flank Adiposity Phase 2
Completed NCT05155683 - Combination of Light and Ultrasound to Reduce Abdominal Fat N/A
Completed NCT03033004 - Cryolipolisis for Abdomen and Flank Fat Reduction N/A